LEGN Legend Biotech
- 40.480
- -1.020-2.46%
Legend Biotech News
Legend Biotech Price Target Maintained With a $90.00/Share by Piper Sandler
Legend Biotech Price Target Maintained With a $90.00/Share by Piper Sandler
Express News | Piper Sandler Reiterates Overweight on Legend Biotech, Maintains $90 Price Target
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Shares of cell therapy company Legend Biotech Corp (NASDAQ:LEGN) were trading lower on Monday, after being among the top pharma gainers in the first week of June.The company's Carvykti drug is likely
Truist Financial Initiates Legend Biotech(LEGN.US) With Buy Rating, Announces Target Price $88
Truist Financial analyst Asthika Goonewardene initiates coverage on $Legend Biotech(LEGN.US)$ with a buy rating, and sets the target price at $88.According to TipRanks data, the analyst has a success
Legend Biotech Initiated at Buy by Truist Securities
Legend Biotech Initiated at Buy by Truist Securities
Piper Sandler Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Piper Sandler analyst Edward Tenthoff maintains $Legend Biotech(LEGN.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success rate of 0.0% an
Express News | Legend Biotech Corp : Truist Securities Initiates Coverage With Buy Rating; Price Target $88
EU to Require Additional Cancer Risk Labeling on CAR T Therapies
HK stocks surged | Genscript Bio (01548) rebounded more than 4%, Legend Biotech announced the results of phase 2 study of its treatment for multiple myeloma drugs.
Genscript Bio (01548) rose more than 4% and as of press time, increased by 4.29%, reporting HKD 9.500, turnover of HKD 8997.52 million.
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
These mid-cap stocks were the best performers in the last week. Are they in your portfolio?Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares soared 29.13% in the last week after reporting that its transf
Goldman Cuts 2seventy Bio to Neutral, Cites Competition Concerns
The total relief rate of Xidacilone race reaches 94%, and sales growth is expected.
On June 4th, Genscript Bio (1548.HK, referred to as "Genscript") announced that its subsidiary, Legend Biotech (LEGN.O), released the results of Phase 2 CARTITUDE-2 (Siltuximab) Cohort D study for the treatment of multiple myeloma patients for the first time at the ASCO Annual Meeting.
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
H.C. Wainwright analyst Mitchell Kapoor maintains $Legend Biotech(LEGN.US)$ with a buy rating, and maintains the target price at $73.According to TipRanks data, the analyst has a success rate of 39.2%
Unveiling 18 Analyst Insights On Legend Biotech
Legend Biotech (NASDAQ:LEGN) has been analyzed by 18 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.In the table below, you'll find a summary of t
Express News | HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Legend Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 82.36% HC Wainwright & Co. $73 → $73 Reiterates Buy → Buy 05/24/2024 82.36% HC Wainwright & Co.
Johnson & Johnson (JNJ.US) and Legend Biotech (LEGN.US) announced positive results from a phase 2 study of SEDAGEN® (idecabtagene vicleucel) for patients with multiple myeloma.
Johnson & Johnson (JNJ.US) and Legend Biotech (LEGN.US) have announced the results of the phase 2 study CARTITUDE-2 cohort D of their product, Ide-cel, for patients with multiple myeloma.
HK stock market anomaly: Genscript Bio (01548) increased by more than 9%, and the legend biotech announced the results of phase 2 clinical trial for the treatment of multiple myeloma at ASCO and EHA.
Genscript Bio (01548) rose more than 9% in early trading, as of press time, it increased by 8.75%, at HKD 8.95, with a turnover of HKD 141 million.
Genscript Bio (01548.HK): Legend Biotech released the earliest data and important subgroup analysis of CARVYKTI for the treatment of multiple myeloma at ASCO and EHA.
On June 3, 2024, Legend Biotech, a global leader in cell therapies, announced for the first time the results of the CARTITUDE-2 Cohort D Phase 2 study for patients with multiple myeloma in Somerset, New Jersey, USA. Data showed that patients who did not achieve complete remission (CR) after autologous stem cell transplant (ASCT) and who received a single infusion of CARVYKTI in combination or not with Lenalidomide could achieve deep and sustained remission.
J&J, Legend Release Promising Results on Carvykti in Earlier Treatment Line
Johnson & Johnson (NYSE:JNJ) and Legend Biotech (NASDAQ:LEGN) said that after a single infusion, the CART-T therapy Carvykti (ciltacabtagene autoleucel) led to durable responses in multiple myeloma patients who didn't achieve complete response after frontline autologous stem cell transplant.
Analysis
Price Target
No Data
